Esperion Therapeutics (ESPR) PT Lowered to $40 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts ESPR Hot Sheet
Price: $3.18 --0%
Rating Summary:
6 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 16 | New: 33
Rating Summary:
6 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 16 | New: 33
Join SI Premium – FREE
Jefferies analyst Michael Yee lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $40.00 (from $53.00) while maintaining a Buy rating.
You May Also Be Interested In
- Fastenal (FAST) PT Raised to $51 at DA Davidson
- LVMH (MC:FP) (LVMUY) PT Lowered to EUR425 at TD Cowen
- Nurix (NRIX) PT Raised to $41 at Stifel Following Q3 Print
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
